Marie Louise Bønnelykke-Behrndtz

Marie Louise Bønnelykke-Behrndtz

Auto-generated profile, based on publicly available information

Marie Louise Bønnelykke-Behrndtz

Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2025 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
KKKaroline Assifuah Kristjansen
Karoline Assifuah Kristjansen
NDNulvin Djebbara-Bozo
Nulvin Djebbara-Bozo
KNKumanan Rune Nanthan
Kumanan Rune Nanthan
MBMarie Louise Bønnelykke-Behrndtz
Marie Louise Bønnelykke-Behrndtz
Purpose Drug repurposing may be an efficient strategy for identifying new cancer treatments. Tranexamic acid (TXA), an antifibrinolytic agent that affects the plasminogen-plasmin pathway, may have potential anticancer effects by influencing tumor cell proliferation, angiogenesis, inflammation, immune response, and tissue remodeling—all crucial processes contributing to tumor progression and metastasis. Objective Evaluate TXA’s anticancer effects across in vitro, animal, and clinical studies to assess its potential as a repurposed cancer drug. Methods The study was designed as a PRISMA-compliant systematic review and meta-analysis. The literature search was conducted in MEDLINE, EMBASE, Web of Science, and the Cochrane Library. In vitro, animal, and clinical studies investigating the anticancer effects of TXA or epsilon-aminocaproic acid (EACA) were included. Animal and clinical studies were critically appraised, and studies with a low risk of bias were included in the meta-analysis. Results Of 4367 identified records, 38 articles were included, collectively reporting findings from 41 in vitro studies, 34 animal studies (n = 843 animals), and seven clinical studies (n = 91 patients). The meta-analysis included nine animal studies and showed a tumor growth reduction in animals treated with TXA compared to controls with a standardized mean difference of – 1.0 (95%CI – 1.5; – 0.4) (p = 0.0002). Equivalently, the majority of in vitro studies reported reduced proliferation, viability, and invasiveness in TXA-exposed tumor cell lines. The clinical studies were considerably susceptible to bias, rendering any conclusions futile. Conclusions TXA shows promise as a repurposed cancer drug, revealing an overall reduction in tumor growth, viability, and invasiveness in animal and in vitro studies.

1 November 2023 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Open access
NWNikolaj Warming
Nikolaj Warming
GTGete Toft
Gete Toft
LBLene Birk-Sørensen
Lene Birk-Sørensen
LBLouise Bønnelykke-Behrndtz
Louise Bønnelykke-Behrndtz
Background: The deep inferior epigastric perforator (DIEP) flap is the gold standard for autologous breast reconstruction. The procedure and peri-operative period are associated with the risk of severe post-operative complications, like venous thromboembolic events (VTE) and lung embolism. Whether the intra-abdominal pressure (IAP) increases after the closure of the abdominal defect, thereby potentially affecting the venous backflow and the risk of VTE, is currently not known.Aim: The primary aim is to test if the closure of the abdominal donor site increases the IAP in women undergoing secondary DIEP flap breast reconstruction.Materials and method: By using a Unometer, we measured the intravesical pressure as a surrogate marker for the IAP, at baseline, immediately after, and 24 h after abdominal skin closure, for 13 patients.Results: The mean IAP increased from 6.1 mmHg (95% CI 4.6-7.7) at baseline to 9.0 mmHg (95% CI 8.0-10.0) immediately after skin closure [mean diff. 2.9 (95% CI 1.0-4.8) (p = 0.007)] and further up to 11.7 mmHg (95% CI 9.0-14.5) 24 h after closure [mean diff. 5.3 (95% CI 1.4-9.1) (p = 0.012)]. We found that IAP varies among the patients, regardless of the tightness of abdominal closure or rectus plication (n = 3). Immediately after closure, none of the isolated patients showed abnormal levels of IAP (> 12 mmHg), while eight out of 12 isolated patients (67%) showed IAP levels above the normal range after 24 h. One patient developed a non-fatal lung embolism.Conclusion: The mean IAP increases significantly over the post-operative period after DIEP flap reconstruction, although abnormal IAP values are only seen 24 h after the closure of the skin.(c) 2023 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd.

28 March 2023 in Cancer Epidemiology
Verified
Journal Article
Closed access
MBMarie Louise Bønnelykke-Behrndtz
Marie Louise Bønnelykke-Behrndtz
KKKasper Bruun Kristensen
Kasper Bruun Kristensen
LHLisbet Rosenkrantz Hölmich
Lisbet Rosenkrantz Hölmich
APAnton Pottegård
Anton Pottegård